COVID-19: Emergency Support for Patients with
To protect the most
vulnerable during COVID-19 by providing the purchase and delivery
of essential chronic care medicines for the upcoming 8 months for
As part of the work
we've been doing to prevent spread of COVID-19, our Club has
recently handed out masks and alcohol gel to 150 low-income
patients with chronic illness who are at risk for COVID-19.
These patients suffering from:
- Parkinson's and
Since it is known that patients with chronic illness are
particularly at risk for complications and death from COVID-19,
and because it is also known that the more these patients have
their chronic illnesses under control with consistent medication,
the less risk they are at for serious illness or death related to
COVID-19, we want to find ways to support these patients.
We would like to continue supporting these patients by purchasing
and delivering to them their needed monthly medications for the
upcoming 8 months to ensure they keep their chronic conditions
under control. This support includes:
- The cost of the medicines for the 150 patients, almost
$4,000 per month.
- Transport and time of our Rotary Community Corps members who
support these patients on a regular basis with home visits
(under normal circumstances, actual home visits have been
suspended during the pandemic).
- Ongoing virtual trainings for the patients via Whatsapp and
other digital forums with the RCC.
The total cost is $35,881. This work would be done through the
existing network of RCC trained health promoters and the Nueva
Vida Clinic, a non-profit project of the Jubilee House Community
serving one of Nicaragua's poorest urban areas and Ciudad
Sandino's most marginalized barrio, Nueva Vida.
Continuing Cost & Impact:
$31,764 medicine costs for 8 months for 150 chronic care
$4,117 support of Rotary
Community Corp efforts for 8 months
Total Cost: $35,881
You and your Club can help:
Contact us via email: email@example.com
Donate online here
a partnering NGO, dedicating your
gift to Rotary Ciudad Sandino COVID-19 response.